Business
Eroxon Awarded “New Product of the Year” by Boots
Eroxon Awarded “New Product of the Year” by Boots.
About this update from Futura Medical Plc
[{"type":"text","content":"\n\n \n2 November 2023\n Futura Medical plc\n(\"Futura\" or the \"Company\")\nEroxon Awarded \"New Product of the Year, Healthcare\" by Boots\n \nFutura Medical plc (AIM: FUM) (\"Futura\" or the \"Company\"), the pharmaceutical company developing innovative sexual health products, announces that Eroxon® has won the \"New Product of the Year, Healthcare\" category at the Boots Supplier Awards 2023, following its UK launch earlier this year. The award is further recognition for Futura's breakthrough treatment for erectile dysfunction (\"ED\") as it provides an alternative treatment option for the 4.3 million men in the UK experiencing symptoms*.\nJames Barder, Chief Executive Officer of Futura said: \"Winning the \"New Product of the Year, Healthcare\" award at this year's Boots Supplier Awards is great recognition for Eroxon® by one of Britain's most trusted brands. Eroxon® is a potential game changer for the 4.3 million men who suffer from ED in the UK and we are delighted to see it getting the recognition it deserves.\"\n*Figures based on men reporting occasional and frequent difficulty getting or maintaining an erection, ref Kantar TNS Omnibus Survey Dec 2010 in a survey of 1,033 men. Stats are UK unless stated otherwise.\n \nENDS\n \nFor further information please contact:\n \nFutura Medical plc\nJames Barder, Chief Executive Officer\nAngela Hildreth, Finance Director and COO\nEmail: [email protected]\nTel: +44 (0) 1483 685 670\nwww.futuramedical.com\n \nFor media enquiries please contact:\nOptimum Strategic Communications\nNick Bastin / Jonathan Edwards/ Zoe Bolt / Elena Bates\nEmail: [email protected]\nTel: +44 (0) 203 882 9621\n \n\nAbout Futura Medical plc\nFutura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Development and commercialisation strategies are designed to maximise product differentiation and value creation wh...